Peptide Therapeutics Market Intelligence by API, Drug Class, Technology, Application, End-user, Region – Global Forecast to 2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Peptide Therapeutics Market Intelligence Report – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering.

The Global Peptide Therapeutics Market is projected to reach USD 50.72 billion by 2027 from USD 27.13 billion in 2021, at a CAGR 10.99% during the forecast period.

In this report, the years 2019 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

The report on peptide therapeutics identifies key attributes about the customer to define the potential market and identify different needs across the industry.

Understanding the potential customer group’s economies and geographies can help gain business acumen for better strategic decision-making. This market coverage across different industry verticals reveals the hidden truth about the players’ strategies in different verticals and helps the organization decide target audience.

This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan.

Key Findings

• The Americas Peptide Therapeutics Market size was estimated at USD 9,961.11 million in 2021, is expected to reach USD 10,955.95 million in 2022, and is projected to grow at a CAGR of 10.64% to reach USD 18,276.41 million by 2027.
• The Asia-Pacific Peptide Therapeutics Market size was estimated at USD 7,286.99 million in 2021, is expected to reach USD 8,218.47 million in 2022, and is projected to grow at a CAGR of 11.62% to reach USD 14,099.32 million by 2027.
• The Europe, Middle East & Africa Peptide Therapeutics Market size was estimated at USD 9,886.49 million in 2021, is expected to reach USD 10,932.62 million in 2022, and is projected to grow at a CAGR of 10.85% to reach USD 18,349.81 million by 2027.

Company Usability Profiles:

• AmbioPharm Inc.
• Amgen Inc.
• AstraZeneca PLC
• Bachem Holding AG
• Bristol-Myers Squibb Company
• CordenPharma International
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Hemmo Pharmaceuticals Pvt Ltd.
• Ipsen S.A.
• Merck & Co., Inc.
• Novartis International AG
• Novo Nordisk A/S
• Pfizer Inc.
• PolyPeptide Group
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Zealand Pharma A/S

Market Segmentation & Coverage:

Technology:

• Hybrid Phase
• Liquid Phase
• Solid Phase

API Type:

• CMO
• In-house

Drug Class:

• Calcitonins
• Glucagon & Analogs
• Insulins
• Luteinizing Hormone-Releasing Hormone
• Somatostatins
• Vasopressin

Application:

• Anti-infective
• Cancer
• Cardio Vascular Disease Respiratory
• Central Nervous System
• Dermatology
• Gastrointestinal
• Metabolic
• Renal

End User:

• Hospitals
• Pharmaceutical Industries
• Research Laboratories

Region:

• Americas
  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
    • California
    • Florida
    • Illinois
    • New York
    • Ohio
    • Pennsylvania
    • Texas
• Asia-Pacific
  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
• Europe, Middle East & Africa
  • France
  • Germany
  • Italy
  • Netherlands
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • United Arab Emirates
  • United Kingdom

For more information about this report visit https://www.researchandmarkets.com/r/5t6k4o

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900